News & Updates

Show Multimedia Only
CDI can hit children without prior antibiotic exposure
CDI can hit children without prior antibiotic exposure
23 Jan 2026 byStephen Padilla

Clostridioides difficile infection (CDI) is possible in children with no previous exposure to antibiotics, especially in community settings, suggests a Japan study, supporting the consideration of changes to current management practices for paediatric CDI.

CDI can hit children without prior antibiotic exposure
23 Jan 2026
Sotrovimab benefits select hospitalized COVID-19 patients
Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026 byAudrey Abella

In the RECOVERY* trial, the neutralizing monoclonal antibody (mAb) sotrovimab reduces mortality in hospitalized patients with COVID-19 pneumonia with a high baseline serum SARS-CoV-2 antigen concentration. However, this was not the case in the overall population.

Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026
Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC
Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC
21 Jan 2026 byChristina Lau

Chinese patients with locally advanced or metastatic, EGFR-mutated, MET-amplified non-small-cell lung cancer (NSCLC) whose disease progressed on first-line (1L) EGFR tyrosine kinase inhibitor (TKI) therapy obtain progression-free survival (PFS) benefit from the all-oral combination of savolitinib plus osimertinib vs platinum-based doublet chemotherapy, interim results of the phase III SACHI trial have shown.

Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC
21 Jan 2026